Drug Profile
Afamitresgene autoleucel - Adaptimmune
Alternative Names: ADP A2M4; afami-cel - adaptimmune; MAGE-A4 SPEAR T-cell therapy; MAGE-A4 TCR; MAGE-A4-SPEAR-T-cell-therapy-Adaptimmune; MAGE-A4ᶜ¹º³²T; Melanoma-associated antigen A4-specific T-cells - AdaptimmuneLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Adaptimmune
- Developer Adaptimmune; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Synovial sarcoma
- Phase II Head and neck cancer; Myxoid liposarcoma; Ovarian cancer
- Phase I/II Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 21 Mar 2024 FDA assigns PDUFA action date of 04/08/2024 for afamitresgene autoleucel for Synovial sarcoma
- 20 Mar 2024 Adaptimmune files for PCT patent protection for afamitresgene autoleucel for treating head and neck, lung, and ovarian cancers
- 20 Mar 2024 Adaptimmune has patent protection for afamitresgene autoleucel and T-cell therapies